Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Karuna Therapeutics management to meet virtually with Mizuho » 13:35
07/08/20
07/08
13:35
07/08/20
13:35
KRTX

Karuna Therapeutics

$98.16 /

-1.61 (-1.61%)

Virtual Meeting to be…

Virtual Meeting to be held on July 13 hosted by Mizuho.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$98.16 /

-1.61 (-1.61%)

KRTX Karuna Therapeutics
$98.16 /

-1.61 (-1.61%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
KRTX Karuna Therapeutics
$98.16 /

-1.61 (-1.61%)

  • 23
    Jan
  • 21
    Nov
KRTX Karuna Therapeutics
$98.16 /

-1.61 (-1.61%)

Conference/Events
Karuna Therapeutics management to meet virtually with JMP Securities » 04:55
07/08/20
07/08
04:55
07/08/20
04:55
KRTX

Karuna Therapeutics

$99.77 /

-0.97 (-0.96%)

Virtual Meeting to be…

Virtual Meeting to be held on July 8 hosted by JMP Securities.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$99.77 /

-0.97 (-0.96%)

KRTX Karuna Therapeutics
$99.77 /

-0.97 (-0.96%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
KRTX Karuna Therapeutics
$99.77 /

-0.97 (-0.96%)

  • 23
    Jan
  • 21
    Nov
KRTX Karuna Therapeutics
$99.77 /

-0.97 (-0.96%)

Over a week ago
Syndicate
Karuna Therapeutics files $150M mixed securities shelf  17:43
07/02/20
07/02
17:43
07/02/20
17:43
KRTX

Karuna Therapeutics

$109.74 /

+3.285 (+3.09%)

 
ShowHide Related Items >><<
KRTX Karuna Therapeutics
$109.74 /

+3.285 (+3.09%)

KRTX Karuna Therapeutics
$109.74 /

+3.285 (+3.09%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
KRTX Karuna Therapeutics
$109.74 /

+3.285 (+3.09%)

  • 23
    Jan
  • 21
    Nov
KRTX Karuna Therapeutics
$109.74 /

+3.285 (+3.09%)

Conference/Events
Karuna Therapeutics management to meet virtually with JMP Securities » 11:14
07/01/20
07/01
11:14
07/01/20
11:14
KRTX

Karuna Therapeutics

$107.58 /

-3.735 (-3.36%)

Virtual Meeting to be…

Virtual Meeting to be held on July 8 hosted by JMP Securities.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$107.58 /

-3.735 (-3.36%)

KRTX Karuna Therapeutics
$107.58 /

-3.735 (-3.36%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
KRTX Karuna Therapeutics
$107.58 /

-3.735 (-3.36%)

  • 23
    Jan
  • 21
    Nov
KRTX Karuna Therapeutics
$107.58 /

-3.735 (-3.36%)

Recommendations
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer » 07:52
06/24/20
06/24
07:52
06/24/20
07:52
KRTX

Karuna Therapeutics

$105.77 /

+1.48 (+1.42%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Karuna Therapeutics to $135 from $125 and keeps an Outperform rating on the shares. The analyst notes that the FDA EOP2 meeting confirmed anticipated details of pivotal Phase 3 program for KarXT in schizophrenia. FDA agreed that one additional positive efficacy trial along with the prior positive Phase 2 trial, plus additional long-term safety data, would be sufficient for NDA filing, he adds. Olson points out that the company plans to initiate the first of two Phase 3 efficacy trials by year-end 2020 with similar design to Phase 2 followed by 52-week open-label extension, and a separate 52-week open-label Phase 3 safety trial in the first half of 2021. The analyst views FDA's clearance of Karuna's development strategy as de-risking, and raises his Probability of Success for KarXT in schizophrenia to 55% from 50%.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$105.77 /

+1.48 (+1.42%)

KRTX Karuna Therapeutics
$105.77 /

+1.48 (+1.42%)

06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
KRTX Karuna Therapeutics
$105.77 /

+1.48 (+1.42%)

KRTX Karuna Therapeutics
$105.77 /

+1.48 (+1.42%)

Hot Stocks
Karuna Therapeutics on track to begin Phase 3 program of KarXT by end of 2020 » 06:38
06/23/20
06/23
06:38
06/23/20
06:38
KRTX

Karuna Therapeutics

$104.29 /

+6.59 (+6.75%)

Karuna Therapeutics…

Karuna Therapeutics announced next steps in the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia following the completion of a successful End-of-Phase 2 meeting with the FDA. The outcome of the meeting supports the progression of KarXT into Phase 3 development. The Company remains on track to initiate the Phase 3 program by the end of 2020. The End-of-Phase 2 discussion was supported by pre-clinical and clinical efficacy data, including results from the previously completed positive Phase 2 trial evaluating KarXT in patients with schizophrenia. The Company and FDA aligned on key elements of the Phase 3 program to support a New Drug Application filing, including the initiation of additional trials evaluating the efficacy and long-term safety of KarXT. The formal minutes from the meeting confirmed that the completed Phase 2 trial, along with one successful Phase 3 efficacy and safety trial, and additional safety data to meet regulatory requirements, would be acceptable to support an NDA filing.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$104.29 /

+6.59 (+6.75%)

KRTX Karuna Therapeutics
$104.29 /

+6.59 (+6.75%)

06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
KRTX Karuna Therapeutics
$104.29 /

+6.59 (+6.75%)

KRTX Karuna Therapeutics
$104.29 /

+6.59 (+6.75%)

Over a month ago
Recommendations
Karuna Therapeutics price target raised to $126 from $117 at Wedbush » 07:48
06/02/20
06/02
07:48
06/02/20
07:48
KRTX

Karuna Therapeutics

$91.43 /

-2.83 (-3.00%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Karuna Therapeutics to $126 from $117 and keeps an Outperform rating on the shares. The analyst notes that the company has provided additional KarXT Phase 2 efficacy/safety data. Her KOL speaker viewed KarXT as a potential "game changer," should the magnitude of effect and limited tolerability issues persist through Phase 3 studies.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$91.43 /

-2.83 (-3.00%)

KRTX Karuna Therapeutics
$91.43 /

-2.83 (-3.00%)

06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
KRTX Karuna Therapeutics
$91.43 /

-2.83 (-3.00%)

KRTX Karuna Therapeutics
$91.43 /

-2.83 (-3.00%)

KRTX Karuna Therapeutics
$91.43 /

-2.83 (-3.00%)

Recommendations
Karuna price target raised to $131 from $115 at Goldman Sachs » 07:05
06/01/20
06/01
07:05
06/01/20
07:05
KRTX

Karuna Therapeutics

$94.26 /

+4.55 (+5.07%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter raised the firm's price target on Karuna Therapeutics to $131 from $115 and keeps a Buy rating on the shares. The company over the weekend presented updated efficacy and safety data at the American Society of Clinical Psychopharmacology meeting demonstrating KarXT's superiority over placebo in schizophrenia psychosis patients, Richter tells investors in a research note. The analyst sees the data update as reaffirming KarXT's "best-in-class" profile, which Richter believes should position the drug favorably in the current treatment paradigm and support advancement to a pivotal trial.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
04/27/20 Oppenheimer
Karuna Therapeutics initiated with an Outperform at Oppenheimer
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

Hot Stocks
Karuna says KarXT superior to placebo in Phase 2 schizophrenia trial » 13:21
05/31/20
05/31
13:21
05/31/20
13:21
KRTX

Karuna Therapeutics

$94.26 /

+4.55 (+5.07%)

Karuna Therapeutics…

Karuna Therapeutics presented on Saturday its Phase 2 trial results for KarXT, a new mechanism antipsychotic based on xanomeline. The drug is superior to placebo in patients with schizophrenia, the company said. The trial enrolled 182 patients with schizophrenia in acute psychotic exacerbation. The patients showed an 11.6-point improvement in PANSS total score at week five for KarXT compared with placebo. The overall adverse event rate for KarXT compared with placebo was 54% versus 43%. These results support Phase 3 development of KarXT for treatment of schizophrenia, according to Karuna. Reference Link

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
04/27/20 Oppenheimer
Karuna Therapeutics initiated with an Outperform at Oppenheimer
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

Recommendations
Karuna schizophrenia drug has blockbuster potential, says Stifel » 13:13
05/31/20
05/31
13:13
05/31/20
13:13
KRTX

Karuna Therapeutics

$94.26 /

+4.55 (+5.07%)

The full Phase 2 data for…

The full Phase 2 data for KarXT, presented over the weekend by Karuna Therapeutics, show a schizophrenia drug that is at least as effective as the standard-of-care but via a totally new mechanism and has a "much improved" tolerability profile than when studied in its prior iteration as xanomeline alone, Stifel analyst Paul Matteis tells investors in a research note. The full results show that for specific types of cholinergic adverse events - nausea, vomiting, dry mouth, constipation - reported rates on KarXT were considerably lower than observed in prior xanomeline trials, says the analyst. Matteis believes the totality of the data suggest that KarXT is "mostly derisked" as an antipsychotic drug and has blockbuster potential. The analyst has a Buy rating on the shares with a $126 price target. Karuna closed Friday up $3.74 to $93.86.

ShowHide Related Items >><<
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

05/28/20 H.C. Wainwright
Karuna Therapeutics initiated with a Buy at H.C. Wainwright
05/08/20 Mizuho
Karuna Therapeutics price target raised to $116 from $103 at Mizuho
04/27/20 Oppenheimer
Karuna Therapeutics initiated with an Outperform at Oppenheimer
03/31/20
Fly Intel: Top five analyst initiations
KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

KRTX Karuna Therapeutics
$94.26 /

+4.55 (+5.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.